Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease
New research indicates that SGLT2 inhibitors can significantly reduce mortality and kidney-related events in patients aged 80 and older with chronic kidney disease. While beneficial, the study notes that these medications carry risks of specific cardiac events and acute kidney injury, necessitating careful monitoring.
Why it matters
This study addresses a critical gap in medical data for elderly patients, who are often excluded from clinical trials, providing guidance for geriatric care.
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Credit: Unsplash/CC0 Public Domain New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.
Headlinne story · 3 newsrooms
New Studies Show Kidney Drugs Benefit Very Old Patients
What every outlet reported, where they differ, and how each framed it →
Also covering this story
2 other newsrooms covered this event. We read each version separately.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in